Prometheus Biosciences

Prometheus Biosciences, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing a broad portfolio of novel precision therapeutics and companion diagnostics to address unmet needs of patients with gastrointestinal and autoimmune diseases. The company has reached an agreement to acquire the rights to LOTRONEX tablets, which are used for female patients with diarrhea-predominant irritable bowel syndrome, as well as an agreement for the development and commercialization of COLAL-PRED, a product in the development stage for treating gastrointestinal disorders or other conditions.